<DOC>
	<DOC>NCT03097133</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder (MDD), including suicidal ideation, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Suicide</mesh_term>
	<mesh_term>Suicidal Ideation</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Participant must meet Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the Mini International Psychiatric Interview (MINI) Participants must have current suicidal ideation with intent, confirmed by a "Yes" response to Question B3 [Think (even momentarily) about harming or of hurting or of injuring yourself: with at least some intent or awareness that you might die as a result; or think about suicide (ie, about killing yourself)?] AND Question B10 [Intend to act on thoughts of killing yourself?] obtained from the MINI In the physician's opinion, acute psychiatric hospitalization is clinically warranted due to participant's imminent risk of suicide Participant has a Montgomery Asberg Depression Rating Scale (MADRS) total score of greater than (&gt;) 28 predose on Day 1 As part of standard of care treatment, participant agrees to be hospitalized voluntarily for a recommended period of 5 days after randomization (may be shorter or longer if clinically warranted in the investigator's opinion) and take prescribed noninvestigational antidepressant therapy(ies) for at least the duration of the doubleblind treatment phase (Day 25) Participant has a current DSM5 diagnosis of bipolar (or related disorders), antisocial personality disorder, or obsessive compulsive disorder Participant currently meets DSM5 criteria for borderline personality disorder. Note: Participant not meeting full DSM5 criteria for borderline personality disorder but exhibiting recurrent suicidal gestures, threats, or selfmutilating behaviors should also be excluded Participant has a current clinical diagnosis of autism, dementia, or intellectual disability Participant has a current or prior DSM5 diagnosis of a psychotic disorder, or MDD with psychotic features Participant has a history of moderate or severe substance or alcohol use disorder, according to DSM5 criteria, except nicotine or caffeine, within 6 months before Screening Participant has a history or current signs and symptoms of liver or renal insufficiency or of clinically significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic (including current or past history of seizures except uncomplicated childhood febrile seizures with no sequelae), hematologic, rheumatologic, or metabolic disease Participant has known allergies, hypersensitivity, intolerance or contraindications to esketamine or ketamine or its excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>